Botulinum toxin B

Drug Profile

Botulinum toxin B

Alternative Names: AN 072; BoNT/B; BotB; Botulinum toxin type B; E 2014; Myobloc; NerBloc; Neurobloc; RimabotulinumtoxinB

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Solstice Neurosciences
  • Developer Eisai Co Ltd; US WorldMeds
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Torticollis
  • Phase III Sialorrhoea

Most Recent Events

  • 01 Jan 2017 US WorldMeds completes the MYSTICOL trial for Sialorrhoea in USA, Russia and Ukraine (NCT01994109
  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2015 US WorldMeds initiates enrolment in the OPTIMYST trial for Sialorrhoea in Ukraine after October 2015 (Intraglandular) (NCT02610868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top